KMT Hepatech earns CCAC accreditation KMT Hepatech has recently applied for and received a Certificate of GAP-Good Animal Practice® from the Canadian Council on Animal Care (CCAC). The CCAC…
KMT Hepatech - 20 yearsFebruary marks 20 years since KMT Hepatech (now part of the PhoenixBio Group) was incorporated. It has been a long journey and a great success…
Rare Disease Day takes place on the last day of February each year since 2008. The main objective of Rare Disease Day is to raise awareness about rare diseases…
Here we summarize 2020 publications where PXB-cells® were used in such application areas as lipid metabolism, toxicity, drug metabolism and hepatitis B.Hata, K. et al. Biomed. Res. 2020; 41(1):33.…
We are pleased to share information on PXB-cells NAFL-like properties first reported on PhoenixBio website.The recently published Letter to Editor (“PXB-cells, fresh primary hepatocytes from humanized mouse livers, exhibit…
An open access paper providing a detailed characterization of PXB-cells® was published in late 2020 in PLoS ONE journal. These cells are proven to be a reliable in vitro…
KMT Hepatech announces changes in executive management Edmonton, December 01, 2020 – KMT Hepatech, Inc. (“KMT”) announced executive management changes. Dr. Norman Kneteman is retired from his position as…
KMT Hepatech (part of PhoenixBio Group) is seeking Production Technologist for the PXB-cells Production and Transplantation Unit. The PXB-cells Production and Transplantation Unit produces cultured PXB-cells (freshly isolated human…
The assessment of safety and the toxicity profile of chemical and biological entities remains a challenge. Despite ongoing efforts to better understand the mechanisms underlying safety and toxicity, ~30%…
Oligonucleotides remain compounds of high interest in drug development, especially with recent advancements in chemistry and delivery technologies. With more compounds progressing further in preclinical development, the need for…
